Hester Biosciences Limited has announced an investor earnings conference call to discuss its financial results for the quarter and year ended March 31, 2026. The intimation was filed with stock exchanges on May 11, 2026, in compliance with Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The call is scheduled for Friday, May 15, 2026, at 2:00 p.m. IST, and will be facilitated by ICICI Securities.

Conference Call Details

The earnings call will feature participation from the company's senior leadership. The following key details summarize the event:

Management Representatives

The conference call will be represented by the following members of Hester Biosciences' senior management:

• Mr. Rajiv Gandhi — CEO & Managing Director
• Ms. Priya Gandhi — Executive Director
• Mr. Ashish Desai — Chief Financial Officer

Call Coordination

ICICI Securities has designated the following coordinators to assist participants with the conference call:

The intimation was signed by Vinod Mali, Company Secretary & Compliance Officer of Hester Biosciences Limited, and submitted to both BSE Limited and the National Stock Exchange of India Limited on May 11, 2026.

Hester Biosciences Limited has submitted a mandatory regulatory declaration confirming that its promoters and promoter group did not create any encumbrances on their shareholdings during the financial year ended March 31, 2026. The declaration was filed with both BSE and NSE on April 3, 2026, in compliance with SEBI regulations.

Regulatory Compliance Declaration

The company filed the declaration pursuant to Regulation 31(4) of SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011. This regulation mandates that promoters and promoter groups must declare annually whether they have created any encumbrances on their shareholdings during the financial year.

Promoter Group Representative

Mr. Rajiv Gandhi submitted the declaration on behalf of the promoters and promoter group. In his communication to the stock exchanges, he confirmed that during the financial year ended March 31, 2026, no encumbrances were made on promoter holdings, either directly or indirectly.

The declaration also requested that this disclosure be presented to the company's Audit Committee for their review and comments, ensuring proper internal governance oversight.

Stock Exchange Communication

The company's Company Secretary and Compliance Officer, Vinod Mali, formally communicated the declaration to both major stock exchanges where Hester Biosciences shares are listed.

Corporate Governance Significance

This annual declaration forms part of the regulatory framework designed to ensure transparency in promoter shareholding patterns. The requirement helps investors and regulators monitor any changes in promoter commitment to their shareholdings through encumbrances such as pledging or hypothecation of shares.

The timely filing of this declaration demonstrates Hester Biosciences' commitment to regulatory compliance and corporate governance standards. Such disclosures are essential for maintaining investor confidence and ensuring transparency in promoter shareholding arrangements.